메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한골다공증학회 OSTEOPOROSIS OSTEOPOROSIS 제6권 제1호
발행연도
2008.1
수록면
8 - 13 (6page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
During the perimenopause, both the quantity and quality of bone decline rapidly, resulting in a dramatic increase in the risk of fracture in postmenopausal women. Data from the large Women's Health Initiative (WHI), in which women with an intact uterus(mean age: 63 years) were randomly assigned to estrogen plus progestin, showed that HT increased total hip BMD and reduced the risk of fractures at the hip, vertebrae, and wrist. Similarly, the estrogen-alone component of the WHI, which involved women(mean age: 64 years) with prior hysterectomy, demonstrated a reduced rate of hip fracture. It is never too early in the menopause to evaluate women for bone loss and advise them on steps to take to prevent the declines in bone mass and quality that increase the risk of future osteoporosis and fracture. Postmenopausal women should therefore be screened for osteoporosis risk factors and have their BMD levels tested, if warranted, in accordance with current guidelines. Use of BMD assists physicians in diagnosing osteoporosis and in monitoring treatment effects. Low-dose hormone therapy and ultralow-dose hormone therapy can provide an effective protection against the postmenopausal decrease of BMD. Estrogen depletion after menopause become involved with postmenopausal bone loss, therefore ET(estrogen therapy) and EPT(estrogen-progestogen therapy) have been considered as first-line therapy for postmenopausal osteopenia and osteoporosis.

목차

등록된 정보가 없습니다.

참고문헌 (22)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0